Effective April 1, 2024, Aetna will remove Humira (adalimumab) from most commercial pharmacy formularies. Impacted plan members will need to switch to a preferred biosimilar or other preferred product.
Affected members will retain access to adalimumab, the same molecule as Humira, through available biosimilars. Biosimilars are FDA-approved biologic medications that have no clinically meaningful difference from another FDA-approved biologic medicine.
This change comes as part of Aetna’s biosimilar-focused pharmacy formulary strategy, supporting the adoption and easy access of biosimilars to increase competition, lower specialty drug costs, and improve member affordability. This strategy is projected to save up to 27 percent in autoimmune class net costs compared to 2022.
More details on Aetna’s commercial pharmacy formulary strategy, and a complete list of impacted formulary changes, are available here.
For more information, contact your Bukaty benefits consultant at 913.345.0440.
